Covered recipient · General Payments record
FRANCINE MANUEL
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$10,098.16
- Reported across 351 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $519.00 | 1 |
| Food and Beverage | $484.15 | 32 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $615.24 | 10 |
| PFIZER INC. | $110.53 | 6 |
| Lilly USA, LLC | $79.85 | 5 |
| Acerta Pharma LLC | $62.58 | 4 |
| Exact Sciences Corporation | $44.99 | 2 |
| Novo Nordisk AS | $31.81 | 2 |
| ABBVIE INC. | $27.68 | 2 |
| Merck Sharp & Dohme Corporation | $16.70 | 1 |
| GlaxoSmithKline, LLC. | $13.77 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.21 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104961576 | CMS |
| ABBVIE INC. | $13.47 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104961578 | CMS |
| Amgen Inc. | $9.76 | 01/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643242 | CMS |
| Amgen Inc. | $519.00 | 01/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1111643260 | CMS |
| Amgen Inc. | $12.89 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643244 | CMS |
| Amgen Inc. | $11.60 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643246 | CMS |
| Amgen Inc. | $10.55 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643248 | CMS |
| Amgen Inc. | $8.92 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643250 | CMS |
| Amgen Inc. | $12.18 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643252 | CMS |
| Amgen Inc. | $8.67 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643254 | CMS |
| Amgen Inc. | $9.64 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643256 | CMS |
| Amgen Inc. | $12.03 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111643258 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.26 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104256677 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.07 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104252113 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.15 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104439813 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.10 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105845339 | CMS |
| Exact Sciences Corporation | $24.17 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114771865 | CMS |
| Exact Sciences Corporation | $20.82 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114771871 | CMS |
| GlaxoSmithKline, LLC. | $13.77 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116617312 | CMS |
| Lilly USA, LLC | $15.34 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134973617 | CMS |
| Lilly USA, LLC | $21.40 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134995876 | CMS |
| Lilly USA, LLC | $13.35 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134989964 | CMS |
| Lilly USA, LLC | $16.43 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134980014 | CMS |
| Lilly USA, LLC | $13.33 | 11/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134980012 | CMS |
| Merck Sharp & Dohme LLC | $16.70 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141844759 | CMS |
| Novo Nordisk Inc | $16.84 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097396390 | CMS |
| Novo Nordisk Inc | $14.97 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096932919 | CMS |
| PFIZER INC. | $18.90 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131033159 | CMS |
| PFIZER INC. | $18.09 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131432084 | CMS |
| PFIZER INC. | $21.75 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131853121 | CMS |
| PFIZER INC. | $18.63 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132091982 | CMS |
| PFIZER INC. | $19.04 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131206603 | CMS |
| PFIZER INC. | $14.12 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131212398 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.